The Greater Manchester Future of Health Challenge has named 15 health technology start-ups to join the 12-week accelerator programme, Novartis has announced.
The company explained that the “intensive” 12-week programme will include training, mentoring and support from leaders in the health and technology space, including Novartis, Google and Salford Royal NHS Foundation Trust, to “create new clinical solutions for patients in Greater Manchester and beyond.”
Ultimately, just 15 participants were selected from over 100 applicants who replied to the call for creative use of new technologies to solve some of Greater Manchester’s most pressing health problems.
Successful businesses include BuddyHub, Cievert, Collabco, Healum, Mind Moose and My Cognition among others.
The programme asked applicant health technology start-ups and entrepreneurs to submit ideas that could be beneficial to one or more of three focus areas, 'Solutions that improve the experience of those with dementia and/or frailty', 'Solutions allowing primary care and outpatient services to be delivered in or near the home for patients' and 'Innovations to allow digital nudges to improve prevention and public health'.
“Medicine is being revolutionised by increasing use of digital technology and data science, and we are committed to using our expertise and resources to unlock the opportunities this offers,” said Emma Hoglund, head of commercial execution and digital strategy at Novartis UK.
“This programme is part of a wider initiative to collaborate with like-minded organisations to create new ideas, solutions and technologies that can help our NHS to provide better patient care. We are pleased to be able to support this programme and wish the participants every success with their projects.”
The Challenge itself is an initiative to identify new solutions based on digital technologies, and is a collaboration between Up Ventures, MediaCityUK, Salford Royal NHS Foundation Trust, Salford Digital, Health Innovation Manchester, Novartis, Push Doctor, Google, and Apadmi.